Is GlaxoSmithKline SAE halal to invest in?

According to Musaffa's Shariah screening methodology, GlaxoSmithKline SAE (BIOC.CA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is GlaxoSmithKline SAE a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GlaxoSmithKline SAE using these criteria to determine its compliance status.

Can Muslims buy shares of GlaxoSmithKline SAE?

Muslim investors may consider investing in GlaxoSmithKline SAE if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is GlaxoSmithKline SAE classified as NOT HALAL?

Musaffa determines the Shariah status of GlaxoSmithKline SAE by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for GlaxoSmithKline SAE updated?

The Shariah compliance status of GlaxoSmithKline SAE may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like GlaxoSmithKline SAE become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of GlaxoSmithKline SAE?

You can check the latest Shariah compliance status of GlaxoSmithKline SAE on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

BIOC.CA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 01, 2026

Report Source: 2025 Annual Report

GlaxoSmithKline SAE. Stock Analysis BIOC.CA

Egypt Health Care Micro Cap Report: 2025 Annual

GlaxoSmithKline (Egypt) engages in the pharmaceutical and healthcare business. The company is headquartered in Cairo, Cairo. In addition, it manufactures and distributes several other licensed products from other companies.

Key Statistics of GlaxoSmithKline SAE (BIOC.CA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

EGP76.00EGP78.00

Today's Open

EGP78.00

Volume

56.83K

P/E Ratio (TTM)

29.97

52 Week Range

EGP34.34EGP81.50

Market Cap

5.85B

Avg. Volume

151.76K

Dividend Yield

0.22%

Financial Metrics & Statements of GlaxoSmithKline SAE (BIOC.CA)

Community-Curated Collections with GlaxoSmithKline SAE (BIOC.CA) ( With BIOC.CA )

View All

Community-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.

EGX (Thndr شريعة)

By Ahmed Essam

5 Followers

+61 more

FAQ's for GlaxoSmithKline SAE (BIOC.CA)

According to Musaffa’s Shariah screening methodology, GlaxoSmithKline SAE (BIOC.CA) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.